Oncology
Pipeline
About our Oncology efforts
We have a clear aspiration – to transform the lives of people with cancer by delivering meaningful advances, with the ultimate goal of curing a range of cancers. Our generational commitment to driving scientific innovation is reflected by our robust pipeline of cancer cell-directed and immuno-oncology investigational therapies, as well as the smart combination of these approaches. We are taking a diligent and broad approach, creating a collaborative research network to tap into a diversity of minds, which is vital in addressing some of the most challenging, but potentially most impactful, areas of cancer research. Simply put, for Boehringer Ingelheim, cancer care is personal, today and for generations.
Oncology
Non-small cell lung cancer
HER2 TKI
Zongertinib (BI 1810631)
Oncology
Small-cell lung cancer
DLL3/CD3 T-cell engager
Obrixtamig (BI 764532)
Oncology
Extra-pulmonary neuroendocrine carcinoma
DLL3/CD3 T-cell engager
Obrixtamig (BI 764532)
Oncology
Non-small-cell lung cancer
MDM2-p53 antagonist
Brigimadlin (BI 907828)